May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s
Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week

Read the full 321 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE